Imprimis Pharmaceuticals (IMMY) Hits New 52-Week High at $4.66

Share on StockTwits

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) hit a new 52-week high on Thursday . The stock traded as high as $4.66 and last traded at $4.56, with a volume of 1654 shares. The stock had previously closed at $4.39.

The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 3.66.

In related news, Director Robert J. Kammer sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $3.00, for a total transaction of $30,000.00. Following the sale, the director now directly owns 919,827 shares of the company’s stock, valued at approximately $2,759,481. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders have sold 30,000 shares of company stock worth $102,100. 13.78% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Granite Investment Partners LLC increased its stake in Imprimis Pharmaceuticals by 44.5% during the 3rd quarter. Granite Investment Partners LLC now owns 247,117 shares of the specialty pharmaceutical company’s stock worth $687,000 after buying an additional 76,155 shares during the period. JPMorgan Chase & Co. increased its stake in Imprimis Pharmaceuticals by 104.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 117,990 shares of the specialty pharmaceutical company’s stock worth $328,000 after buying an additional 60,248 shares during the period. Ardsley Advisory Partners grew its holdings in Imprimis Pharmaceuticals by 42.9% during the 2nd quarter. Ardsley Advisory Partners now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $220,000 after acquiring an additional 30,000 shares in the last quarter. Birchview Capital LP acquired a new position in Imprimis Pharmaceuticals during the 2nd quarter worth approximately $396,000. Finally, Northern Trust Corp grew its holdings in Imprimis Pharmaceuticals by 145.8% during the 1st quarter. Northern Trust Corp now owns 67,013 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 39,750 shares in the last quarter. 8.55% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Imprimis Pharmaceuticals (IMMY) Hits New 52-Week High at $4.66” was posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://baseballnewssource.com/2018/11/10/imprimis-pharmaceuticals-immy-hits-new-52-week-high-at-4-66/2972540.html.

Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)

Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.

See Also: Outstanding Shares

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.